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ABSTRACT 
 
BACKGROUND: Breast cancer is the leading cancer in Malaysia and among 
women. Annona Muricata or Graviola leaves or Soursop leaves also known as ‘the 
cancer killer’ has been used worldwide as a complementary for treatment of cancer. 
Many studies have shown that Annona Muricata has a potential of anti-
tumorigenicity and chemoprevention to treat cancer. Hence, in this study, we are 
trying to proof the cytotoxic effect and metastatic effect of Annona Muricata on 
breast cancer cell lines. 
 
OBJECTIVE: This study aims to determine the cytotoxic effect of the extract of the 
soursop (Annona Muricata) leaves, the apoptotic effect and effect on cell cycle after 
treatment of the extracts on the MDA-MB 231 and MCF-7 breast cancer cell lines. 
 
MATERIALS AND METHODS: Extracts from Annona Muricata was prepared 
using soxhlet method using different solvents (hexane, Ethyl acetate, methanol and 
water). MDA-MB 231 (ER/PR negative) and MCF-7 (ER/PR positive) breast cancer 
cell line used in the study. The cytotoxic effect was analysed by counting the number 
of cells inhibition and identified the IC50 (the percentage of cell populations inhibited 
by 50% after treatments) of each extracts, the cell proliferation was observed under 
microscope. The apoptotic effect of MDA-MB 231 and MCF-7 breast cancer cell line 
 xiv 
 
was done by using Annexin V-Fitc Apoptosis Dtec Kit (6140592[1] (31.10.2017). 
While, the effect of cell cycle of MDA-MB 231 and MCF-7 breast cancer cell line 
was done by using Cycletest plus DNA Reagent Kit (6193798[1] (31.07.2017). Both 
tests are then analysed using flow cytometer. 
 
RESULTS: From the experiment, ETAC was the best extract for observing cytotoxic 
effect for MDA-MB 231 cells line and hexane was the best extract for MCF-7 cells 
line. There was a decreased of the number of cells populations for both MDA-MB 
231 and MCF-7 cells line after treatment with Annona Muricata in different 
concentrations and time. ETAC and hexane gave best apoptotic effect at late phase of 
apoptosis, while Tamoxifen gave best apoptosis effect during early phase. Besides, 
there was significant G1 phase arrest of MDA-MB 231 and MCF-7 cells line after 
treatment with ETAC and hexane, respectively, as well as Tamoxifen. There was 
suppression for migration for MDA-MB 231 and MCF-7 cells lines after treatment 
with ETAC and hexane. 
 
CONCLUSIONS: Annona Muricata has a potential of anti-tumorigenicity on MCF-
7 and MDA-MB 231 breast cancer cell lines. It gives changes in morphology of the 
breast cancer cell, as well as cytotoxic and apoptotic effect. Moreover, Annona 
Muricata also induces G1 cell cycle arrest in breast cancer cell lines. In addition, 
soursop leaves can help inhibit breast cancer migration that suggested of metastatic 
prevention. Thus, Annona Muricata can be recommended for use as complement in 
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breast cancer patient and as prevention for tumour occurrence. Even though the 
potential anti-tumorigenicity of Annona Muricata can be observed in this study, 
Tamoxifen still gave better result compared to Annona Muricata in term of cell 
inhibition and metastatic effect. 
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ABSTRAK 
 
LATAR BELAKANG: Kanser payudara adalah kanser yang paling utama 
dikalangan wanita di Malaysia. ‘Annona Muricata’ atau daun ‘Graviola’ atau daun 
durian belanda, juga dikenali sebagai “daun pembunuh kanser’ sudah digunakan di. 
seluruh pelusuk dunia. Banyak kajian dijalankan telah membuktikan bahawa ‘Annona 
Muricata’ mempunyai potensi untuk menyahtumor dalam merawat penyakit kanser. 
Oleh itu, kajian ini dijalankan untuk mengenalpasti kesan sitotosik dan ‘metastatik’ 
daun ini ke atas sel-sel kanser payudara. 
 
OBJEKTIF: Kajian ini dijalankan bertujuan untuk menentukan kesan ‘sititosik’, 
kesan apoptosis dan juga kesan kitaran pembahagian sel-sel selepas sel-sel ‘MDA-
MB 231’ dan ‘MCF-7’ kanser payudara mendapat rawatan ektrak ‘Annona Muricata’ 
 
BAHAN DAN CARA: Ektrak- ekstrak dari ‘Annona Muricata’ dihasilkan melalui 
kaedah ‘soxhlet’ dengan menggunakan ‘solvent’ yang berbeza (‘hexane’, ‘ethyl 
acetate’, ‘methanol’ and air). ‘MDA-MB 231’ dan ‘MCF-7’ sel-sel payudara telah 
digunakan di dalam kajian ini. Kesan sitotosik telah dianalisa menggunakan cara 
pengiraan sel-sel dan IC50 (peratusan populasi apabila sel-sel berkurangan menjadi 
50%) bagi setiap ekstrak dikenalpasti, pembahagian sel telah diperhatikan di bawah 
mikroskop. Kesan apoptosis sel-sel kanser payudara ‘MDA-MB 231’ dan ‘MCF-7’ 
 xvii 
 
dilakukan dengan menggunakan ‘Annexin V-Fitc Apoptosis Dtec Kit’ (6140592[1] 
(31.10.2017). Manakala, kesan kitaran pembahagian sel-sel kanser payudara ‘MDA-
MB 231’ dan ‘MCF-7’ dilakukan dengan menggunakan ‘Cycletest plus DNA 
Reagent Kit’ (6193798[1] (31.07.2017). Kedua-dua ujian ini kemudian dianalisa 
dengan menggunakan mesin ‘flow cytometer’. 
 
KEPUTUSAN: Daripada eksperimen yang telah dijalankan, ‘ETAC’ adalah ekstrak 
yang terbaik untuk sel-sel ‘MDA-MB 231’ dan ‘hexane’ adalah ekstrak yang terbaik 
untuk sel-sel ‘MCF-7’. Terdapat penurunan di dalam jumlah populasi sel-sel ‘MDA-
MB 231’ and ‘MCF-7’ selepas diberi rawatan di dalam kepekatan dan masa yang 
berbeza. ‘ETAC’ dan ‘hexane’ telah memberi kesan apoptosis yang terbaik pada 
peringkat akhir dalam proses apoptosis. Walaubagaimanapon, Tamoxifen memberi 
kesan apoptosis di peringkat awal proses apoptosis. Selain dari itu, selepas rawatan 
oleh ‘ETAC’ dan ‘hexane’, telah terbukti proses kitaran pembahagian sel terbantut 
pada fasa G1, begitu juga Tamoxifen. Melalui eksperimen ini juga terbukti bahawa 
‘Annona Muricata’ bertindak menghalang migrasi sel-sel kanser payudara.  
 
KESIMPULAN: ‘Annona Muricata’ mempunyai potensi penyah-tumor untuk sel-sel 
‘MDA-MB 231’ dan ‘MCF-7’. Annona muricata juga memberi kesan di dalam 
perubahan sel-sel, mempunyai kesan yang baik di dalam proses apoptosis dan 
menghalang kitaran pembahagian sel pada fasa G1, di samping menghalang migrasi 
sel-sel kanser payudara. Oleh itu, ‘Annona Muricata” boleh disyorkan untuk 
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diberikan kepada pesakit – pesakit kanser tahap empat dan digunakan sebagai 
pencegahan sebelum mendapat kanser. Di dalam kajian ini, walaupon kesan 
penyahtumor oleh Annona Muricata telah terbukti, Tamoxifen tetap memberi kesan 
yang terbaik jika dibandingkan dengan ekstrak dari Annona Muricata dari segi 
pengurangan sel-sel dan kesan ‘metastasis’. 
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1. INTRODUCTION 
 
1.1 Background of Study 
 
Breast cancer (BC) is imposing life-threatening issue in the health care of 
women in this era. From World Health Organization WHO data, BC has increased 
in incident and has become the highest among the other cancer types in women 
(National Breast Cancer Foundation, 2015). 
 
Studies in genetic molecular genetic has shown that mutation within genes 
such as p53, BRCA1 and BRCA2 are the main cause of the development of BC in 
women, even though the pathophysiology of occurrence of BC still debatable 
(Schumaker, 2006; Yip et al., 2014). The unhealthy life-style and dietary practice 
could be the contributing factors towards the observation of increase incidence of 
BC (Yip et al., 2006).  
 
The prognostic factors of BC are determined by tumour histological 
grading, nodal and organ involvement and immunohistochemistry (IHC) of the 
tumour. In northern region of Malaysia most of the BC patients presented at 
advanced stage of disease (Norsa adah et al., 2005). The management of advanced 
disease would involve in palliative chemotherapy in the effort of palliation. The 
chemotherapy imposes risks and unwanted side effects to the patients. 
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In Malaysia, complementary medicine is widely practiced and favourable 
among the Malaysian. It does not cure but it provides an improvement to the 
quality of life where as our conventional chemotherapy prolonging the life 
expectancy of these advanced BC patients. More emerging studies are required to 
support the practice of complementary medicine especially in natural products and 
herbal medicine in oncology patients.  
 
Many studies have shown that complementary medicine has benefits to 
help in such of patients’ condition, thus making such treatment a popular and 
alternative option to treat illnesses (Mantena et al., 2006). Hence, this study was 
done to prove that Annona Muricata has cytotoxic effect and anti-metastatic effect 
on breast cancer cells line. 
 
 
1.2 Rationale of Study 
 
The management of BC is depending to the TNM staging of the disease. 
The conventional treatment is surgery followed by adjuvant chemotherapy and 
radiotherapy.  In certain stage of the disease, neoadjuvant chemotherapy may be 
offered to the patient prior to the definitive surgery. The prognosis is significantly 
better when treatment is given at the early stage of the disease. 
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However, the unwanted or unpleasant systemic side effects of the 
chemotherapy impose a wrong impression to patients which leads them to 
stigmatize towards chemotherapy.  
 
The reports from previous study shows that the BC patients who uses 
complementary medicine during and beyond their conventional treatment manage 
better in terms of their symptoms, prevention of toxicities, pain control and quality 
of life (Greenlee et al., 2014). The introduction of complementary medicine and 
herbal medicine gives a new episode in the management of BC.  
 
With more promising study published, complementary medicine should be 
offered together and adjunct along with the conventional medicine to improve 
quality of life of these BC patient. It was shown to act synergistically with 
chemotherapy, increasing the efficacy of chemotherapy (Cheng et al., 2016). 
Furthermore, it may also act as chemoprevention supplement to prevent from 
development of cancer (Moghadamtousi et al., 2014b). 
 
This research was designed to study the potential anti-tumour effect of 
Annona Muricata on MCF-7 and MDA-MB 231 breast cancer cell line. The study 
will evaluate the apoptotic effects, cell growth arrest and anti-metastatic effects of 
Annona Muricata on both BC cell lines. 
 
Soursop leaves or Graviola leaves or Annona Muricata has been chosen for 
this study in view of its potential of anti-tumour effect that  was already well-
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known world-wide (Moghadamtousi et al., 2014a). These leaves were used as 
complementary medicine since decades.  
 
Many studied have been done proved that Annona Muricata has good 
cytotoxic effect on cancer cells (Rachman et al., 2012). It can induce apoptosis and 
also arrest G1 phase of cell-cycle (Moghadamtousi et al.,2014b). Furthermore, 
Annona Muricata also inhibits cells migration, hence; prevent the metastasis of 
cancer cells (Moghamtousi et al., 2014b). 
 
All the above properties render the leaves suitable as cancer prevention and 
for usage in advanced cancer patients.     
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2. LITERATURE REVIEW 
 
2.1 Breast Cancer 
 
The incidence of cancer is increasing in trend in Malaysia. Based on latest 
Health Facts 2013, released by Ministry of Health Malaysia, cancer is one of the 
highest causes of hospitalisation and among the five highest causes of death in 
Malaysia (Ferlay, 2015). In 2006, breast cancer (BC) was leading cancer  in 
Malaysia and was reported to be the highest among the Malaysian women (Yip et 
al., 2006).  
 
Figure 1 showed that BC (17.7%) is the highest cancer among other cancers 
in Malaysian population, followed with colorectal cancer (13.2%) and lungs 
(10.2%) (National Cancer Registry, 2011). Furthermore, BC is three times higher 
compared to colorectal and cervical cancer among women in Malaysia, as showed 
in Figure 2. 
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Figure 1: Ten most frequent cancers in Malaysia 2007-2011. (Adapted from; 
National Cancer Registry Report; Malaysia Cancer Statistic 2007-2011) 
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Figure 2: Ten most frequent cancers in females, Malaysia 2007-2011.  (Adapted 
from; National Cancer Registry Report; Malaysia Cancer Statistic- Data and Figure; 
2007-2011) 
1. 
I ci ence pe 100 ODD 
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Unfortunately, the rate of BC in Malaysia is increasing by years. The report 
from GLOBOCAN 2012 showed further increment in the incidence of BC in 
Malaysia to 28% compared to 6 years ago which was 18% as shown in the Figure 
3. While, the mortality rate of BC patients is around 24.7% (Figure 4) (Ferlay, 
2015).  
 
 
 
 
Figure 3: The incidence of cancers in Malaysia in 2012. (Adapted from; 
International Agency for Research in Cancer (GLOBOCAN, 2012) 
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Figure 4: The percentage of mortality case of cancers in Malaysia in 2012. (Adapted 
from; International Agency for Research in Cancer (GLOBOCAN, 2012) 
 
 
 
The National Cancer registry (NCR) 2003-2005 reported as Age-
Standardised Rate (ASR) of 47.3 per 100,000 (Malaysia Cancer Statistics, 2006). 
The International Agency for Research in Cancer (GLOBOCAN) 2012 estimated 
the ASR of BC in Malaysia as 38.7 per 100000 with 5410 new cases in 2012 (Yip 
et al., 2014) (Figure 5). 
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Figure 5: Estimated age-standardised rate and mortality in Malaysia. (Adapted from; 
International Agency for Research in Cancer (GLOBOCAN, 2012) 
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BC is more common found in the Chinese population in comparison to the 
Indian and Malay population. According to Clinical Practice Guidelines of 
management of breast cancer, Chinese women had the highest incidence with an 
ASR of 46.4 per 100 000 populations followed by Indian women with an ASR 
38.1 per 100 000 populations and Malay women with an ASR 30.0 per 100 000 
populations (Khatcheressian et al., 2013). This is probably due to genetic 
predisposition among the Chinese. Furthermore, it was known that Chinese has 
better awareness about BC compared to Malay. 
 
Table 1: Incidence of breast cancer per 100 000 populations (CR) and Age-
Standardised Incidence (ASR), by Ethnicity and Sex, Peninsular Malaysia 2006 
(Khatcheressian et al., 2013).  
 
Ethnic Group 
Incidence 
No % CR ASR 
Malay 1,539 47.6 25.3 30.4 
Chinese 1,375 42.5 53.2 46.4 
Indian 320 9.9 34.9 38.1 
 
Most of Malaysian women have poor survival from BC and it is estimated 
that half of the death due to BC could be prevented (Yip and Taib, 2012). Table 2 
showed the list of study that had been done by various researches concerning the 
risk factors of BC among Malaysian.  
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Table 2: Risk factor of breast cancer in Malaysia. (Adapted from; Yip, C. H., Bhoo 
Pathy, N. & Teo, S. H. (2014). A review of breast cancer research in Malaysia. Med J 
Malaysia) 
Author 
(year) 
Controls 
(n) 
Cases (n) Recruitm
ent 
Factors that 
reduce risk 
Factors that increase 
risk 
Factors that are 
not significant 
Matalqah et 
al (2011) 
150 150 Penang 
General 
Hospital 
Low fat diet, 
education >11 
years, breast 
feeding, being 
employed 
Family history, benign 
breast disease, 
menstrual irregularity, 
use of oral 
contraceptive (OCP) 
 
Razif et al 
(2011) 
216 216 HKL and 
UKMMC 
Higher number of 
life births 
Family history Age at first child 
birth and 
menarche not 
signficant 
Norsa’adah 
et al (2005) 
147 147 Kelantan Breast feeding Nulliparity, 
overweight, family 
history, use of OCP 
 
Hejar et al 
(2004) 
89 89 Chinese, 
HKL and 
UMMC 
Breast feeding   
Kamarudin 
et al (2006) 
203 203 HKL Exercise, low fat 
diet, longer 
duration of breast 
feeding 
  
Rejali (2007) 62 62 Malayan 
Hospital 
Higher intake of 
selenium 
Nulliparity, exposure 
to cigarette smoke, 
use of OCP 
 
Shahar et al 
(2010) 
70 138 Klang 
Valley 
Higher intake of 
selenium 
Abdominal obesity, 
physical inactivity, low 
serum adiponectin 
 
Sulaiman et 
al (2011) 
382 382 Kuala 
Lumpur 
  Total fat and fat 
subtypes not 
associated 
Suzana et al 
(2009) 
64 127 Klang 
Valley 
Higher intake of 
selenium, vit A, 
Vit E 
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CON’T       
Author 
(year) 
Controls 
(n) 
Cases (n) Recruitm
ent 
Factors that 
reduce risk 
Factors that increase 
risk 
Factors that are 
not significant 
Sharhar et 
al (2008) 
57 139 Klang 
Valley 
 Poor antioxidant 
status and oxidative 
stress measured by 
higher levels of 
malondialdehyde 
(MDA) 
 
Shahril et al 
(2013) 
382 382 Kuala 
Lumpur 
Higher Healthy 
Eating Index-2005 
(HEI-2005) 
  
Ho et al 
(2009) 
37pre-
menopaus
al 
68 post-
menopaus
al 
36pre-
menopaus
al 
66 post-
menopaus
al 
Kuala 
Lumpur 
 Higher serum 
progesterone and 
testosterone levels in 
postmenopausal 
women 
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Table 3: Risk factor for breast cancer in Malaysia (Modified from; Yip, C. H., 
Taib, N. A. & Mohamed, I. (2006). Epidemiology of breast cancer in Malaysia. 
Asian Pac J Cancer Prev) 
 
Increasing age 
Geographic location 
Family history 
Reproductive factors 
                  Early menarche less than 11 years 
                  Late Menopause more than 55 years 
                  Nulliparous 
                  Late first child-b irth more than 30 years 
Carcinoma of uterus 
Carcinoma of ovary 
dietary factors – diet rich in animal fat 
Exogenous hormones – oral contraceptives 
                 Hormonal replacement therapy 
Alcohol – more than 2 drinks per day 
Postmenopausal obesity 
Higher socioeconomic group 
Limited breast feeding (for long periods is a protective factor) 
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2.2 Management of breast cancer 
 
The common practice for diagnosis of BC is via triple assessment, which 
consist of clinical history and physical examination, tissue biopsy and radiological 
assessment. 
Table 4: TNM staging for breast cancer (7th Edition) (Adapted from American joint 
Committee of Cancer, (Giuliano et al., 2017). 
Staging Description 
  
Tx Primary cannot be ruled out 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) DCIS 
Tis (LCIS) LCIS 
Tis (Paget) Paget disease of nipple NOT associated with invasive carcinoma and 
(DCIS and or LCIS) in the underlying breast parenchyma. 
Carcinomas in the breast parenchyma associated with Paget disease 
are categorized based on the site and characteristic of the 
parenchymal disease, although the presence of Paget disease should 
still be noted 
T1 Tumor ≤20mm in greatest dimension 
T1mi Tumor ≤ 1mm in greatest dimension 
T1a Tumor > 1mm but < 5mm in greatest dimension 
T1b Tumor > 5mm but < 10mm in greatest dimension 
Cont. Table 4  
T1c Tumor > 10mm but < 20mm in greatest dimension 
T2 Tumor > 20mm but < 50mm in greatest dimension 
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T3 Tumor >50mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall and/or to 
the skin (ulceration or skin nodules) 
T4a Extension to the chest wall, NOT including only pectoralis muscle 
adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema 
(including peau d’orange) of the skin, which do not meet the criteria 
for the inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Nx Regional LN cannot be assessed (e.g.: previously removed) 
N0 No regional LN 
N1 Metastases to movable ipsilateral level I, II axillary LN 
N2 Metastases in ipsilateral level I, II axillary LN that are clinically 
fixed or matted OR metastases in clinically detected ipsilateral 
internal mammary in the absence of clinically evident axillary LN 
N2a Metastases in ipsilateral level I,II axillary LN fixed to one another 
(matted) or to other structures 
N2b Metastases only in clinically detected ipsilateral internal mammary 
node and in the absence of clinically evident level I, II axillary LN 
N3 Metastases in ipsilateral infraclavicular (level III axillary) LN with or 
without level I, II axillary LN involvement OR metastases in 
clinically detected ipsilateral metastases OR metastass in ipsilateral 
supraclavicular LN with or without axillary or internal mammary LN 
involvement 
N3a Metastases in ipsilateral infraclavicular LN 
N3b Metastases in ipsilateral internal mammary LN and axillary LN 
N3c Metastases in ipsilateral supraclavicular L 
Mx Metastases cannot be assessed (e.g.: previously removed) 
M0 No metastases 
M1 Metastases  
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The management of BC involves the commitment from multidisciplinary 
team approach depending on the stage of the disease. Surgery is considered the 
mainstay of treatment for BC, with chemotherapy, radiotherapy and hormonal 
therapy utilised as adjunctive therapy (Yip et al., 2014).  
 
The Surgical Guidelines for the Management of BC stated that there are two 
teams that should be involved in the management of BC patient. First team is the 
diagnostic team; consist of breast specialist clinician (a consultant surgeon), 
radiologist, and pathologist breast care nurse. Second team is the cancer treatment 
team, which include the diagnostic team, oncologist, plastic and reconstructive 
surgeon and/or onco-plastic breast surgeon, medical prosthetist, psychologist and 
palliative care team (BASO, 2009). 
 
After staging the disease, the patients are categorised into two categories, 
operable or inoperable. For inoperable disease, the option is neoadjuvant 
chemotherapy to downstage the tumour followed by surgery. For operable disease, 
surgery is the gold standard followed by adjuvant radiotherapy, chemotherapy, 
hormonal therapy and targeted therapy.  
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2.3 Tumorigenicity 
 
Tumour literally means “new growth”. It is defined as an abnormal mass of 
tissue growth which exceeds and is coordinated with that of the normal tissues. 
The tissue growth persists in the same excessive manner after the cessation of the 
stimuli that lead to tumour development. As we know, tumour can be benign or 
malignant. Benign tumours are composed of well differentiated cells that closely 
resemble their normal counterparts, slow growth and have no invasion or 
metastasis characteristic. In the other hand, malignant tumours are opposite 
characteristics where they are usually undifferentiated cells, rapid growth and has 
characteristic of invasiveness and metastasis (Kamb, 1995). 
 
Tumorigenicity is a process of a cells/tissues becoming tumour. This process 
happens on the intracellular level due to faulty to repair or error in growth 
signalling in the genetic level. According to study done by Astirin, O.P et al 
(2013), incidence of cancer is associated with the increase in the expression or 
mutation of gene that trigger cancer and the decrease in expression of  cancer 
suppressor gene (Astirin et al., 2013). The absence of DNA-repair enzymes also 
plays an important role in the raise of cancer incidence. As we know, cancer 
suppressor gene has a crucial function in cell homeostasis to prevent tumour 
occurrence (Astirin et al., 2013). Deregulation of cancer suppressor gene can lead 
to cancer progression.  
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P53 is a tumour suppressor gene that regulates the normal cell cycle. It is an 
essential protein to suppress cancer. The function is to arrest cell growth by 
arresting the cell cycle at the G1/S regulation point upon DNA damage recognition. 
This allows the cell to have time to fix the damage. In addition, p53 also can initiate 
the apoptosis, if DNA damage proves to be irreversible (Sheikh et al., 1998). Thus, 
the incidence of cancer also associated with the abnormal process of apoptosis. 
 
Hence, literally, anti-tumorigenicity is a reversible process to prevent or 
counteract the formation of tumour. Mode of cell death can be implemented 
through necrosis, apoptosis and aging. Necrosis and apoptosis have different entity 
and mechanism of action, even though there is certain characteristic of overlap 
properties.  
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2.3.1 Necrosis 
 
 
Necrosis is an irreversible process of cell death that triggered by external 
factor such as hypoxic, acidic environment, toxic and injury. There will be 
changes in morphology of the cell, where the cells become swollen with formation 
of cytoplasmic vacuoles, blebbed cytoplasm and also condense and swollen 
mitochondria (Cotran, 2010). 
 
 
 
2.3.2 Apoptosis 
 
Apoptosis is defined as programmed cell death that is important to maintain 
equilibrium in tissue (Peter, 2011). Apoptosis is a crucial process in the human 
body. If the process fails, the tissue will continuously proliferate and will result in 
the formation of tumour. The characteristics of cells during apoptosis are similar to 
necrosis, except, the cells shrunk rather than swollen. There is presence of apoptotic 
body with condensation of chromatin and DNA fragmentation in the cytoplasm and 
nucleus (Cotran, 2010).  
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Table 5: The differences between apoptosis and necrosis (Adapted from Robin and 
Contran, Pathology Basis Of Disease, 8th Edition, 2010) 
Differential features of apoptosis and necrosis 
Apoptosis Necrosis 
Affects single cells 
No inflammatory response 
Cell shrinkage 
Affects groups of neighbouring cells 
Significant inflammatory response 
Cell swelling 
Membrane blebbing but integrity 
maintained 
Loss of cell integrity 
Increased mitochondria membrane 
permeability, release of proapoptotic 
proteins and formation of apoptotic 
bodies 
Organelle swelling and lysosomal 
leakage 
Chromatin condensation and non-
random DNA fragmentation 
Random degradation of DNA 
Apoptotic bodies ingested by 
neighbouring cells 
Lysed cells ingested by macrophages 
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2.4 Cell Cycle 
 
The proliferation of a cell is a regulated process that involves a large number 
of molecules and interrelated pathways. The replication of cells is stimulated by 
growth factors by signalling extracellular membrane components through integrin 
(Cotran, 2010). The proliferation process of cell cycle is to achieve DNA replication 
and division. 
 
Cell cycle consists of presynthetic (G1), DNA synthesis (S), Premitotic (G2) 
and mitotic (M) phases. G0 phase is the phase where the quiescent cells that have 
not entered the cell cycle reside. Each of the transition is important step in cell 
cycle.  The first transition in the process is from G0 to G1. This is where the 
activation of transcription genes, including various proto-oncogenes and genes 
required for ribosome synthesis and protein translation. The critical transition is at 
the G1 to S transition called restriction point, which is  a rate-limiting step for 
replication (Cotran, 2010).  
 
The assessment for damaged DNA occurs twice and there is often referred to 
checkpoint. First checkpoint is at the G1/S checkpoint that ensures that the damaged 
DNA or chromosomes do not complete the replication and to monitor the integrity 
of DNA before replication (Mantena et al., 2006). The second checkpoint is the 
G2/M checkpoint where it checks the DNA after replication and monitors whether 
the cell can safely enter mitosis or not (Cotran, 2010). If there is DNA damaged, 
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checkpoint activation delays the cell cycle and trigger DNA repair. However, if the 
damaged is too severe, they are eradicated by the process of apoptosis. On the other 
hand, if the checkpoint is defective, the cell will continuously be replicating and 
dividing, which is the basis of tumour formation (Kamb, 1995). Figure 6 
summarized the process of cell cycle. 
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Figure 6: The image above shows the schematic diagram of cell cycle (Adapted 
from Robin and Contran, Pathology Basis of Disease, 8th Edition, 2010) 
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